ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 2130

Enrichment of IL-17-producing CD4+ T Cells in Synovial Fluid from Patients with Arthritis After anti-CTLA-4 and anti-PD-1 Combination Therapy

Sang Kim1, Jean Tayar 1, Maria E. Suárez-Almazor 2, Huifang Lu 1, Yang-Zhi Zhao 1, Zhongshan Liu 3, Emma Rodriguez 1, Sattva Neelapu 1, Jennifer Wang 1, Amishi Shah 1, Nizar Tannir 3, Don Gibbons 3, Guillermo Garcia-Manero 3, Hussein Tawbi 3, Patrick Hwu 1, Andrew Futreal 3, Adi Diab 3 and Roza Nurieva 3, 1MD Anderson Cancer Center, Houston, TX, 2Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX, 3MD Anderson Cancer Center, Houston

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: , ,

Session Information

Date: Tuesday, November 12, 2019

Session Title: Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Understanding the pathophysiology of arthritis-irAE is critical to treating it without impeding antitumor immunity; however, these mechanisms remain elusive. As a first step in elucidating these mechanisms, we characterized functional immune cell profiles in synovial fluid from patients with arthritis-irAE.

Methods: We collected and performed immunoprofiling of synovial fluid from seven patients with active arthritis-irAE who received ICIs and three control patients with osteoarthritis who did not receive ICIs.

Results: Four patients developed arthritis after PD-1 inhibitor monotherapy and three after combination therapy with CTLA-4 and PD-1 inhibitors. Two patients in the combination therapy group required interleukin (IL)-6 receptor inhibitor therapy in addition to steroids, compared with one patient in the monotherapy group (sulfasalazine). IL-17-producing CD4+ T cells (Th17) were enriched in the combination therapy group (1.01±0.73% live CD4+ T cells in the monotherapy group compared with 3.19±0.31% in the combination therapy group; P=0.005). Synovial fluid levels of IL-6 and IL-17A, key cytokines for Th17 cell differentiation and function, were higher in the combination therapy group than in the monotherapy group, although this difference was not statistically significant.

Conclusion: Our results demonstrate that combination therapy with CTLA-4 and PD-1 inhibitors may result in enhanced incidence of steroid-resistant arthritis-irAE. Th17 cells were enriched in the synovial fluid of arthritis-irAE patients with combination therapy, suggesting their role in disease pathophysiology. Further studies with more cases and controls are needed to better understand the mechanisms underlying arthritis-irAE.

Disclosure: S. Kim, None; J. Tayar, None; M. Suárez-Almazor, Bristol-Myers Squibb, 5, Pfizer Inc, 5, Eli Lilly, 5; H. Lu, None; Y. Zhao, None; Z. Liu, None; E. Rodriguez, None; S. Neelapu, None; J. Wang, None; A. Shah, None; N. Tannir, None; D. Gibbons, None; G. Garcia-Manero, None; H. Tawbi, None; P. Hwu, None; A. Futreal, None; A. Diab, None; R. Nurieva, None.

To cite this abstract in AMA style:

Kim S, Tayar J, Suárez-Almazor M, Lu H, Zhao Y, Liu Z, Rodriguez E, Neelapu S, Wang J, Shah A, Tannir N, Gibbons D, Garcia-Manero G, Tawbi H, Hwu P, Futreal A, Diab A, Nurieva R. Enrichment of IL-17-producing CD4+ T Cells in Synovial Fluid from Patients with Arthritis After anti-CTLA-4 and anti-PD-1 Combination Therapy [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/enrichment-of-il-17-producing-cd4-t-cells-in-synovial-fluid-from-patients-with-arthritis-after-anti-ctla-4-and-anti-pd-1-combination-therapy/. Accessed September 19, 2021.

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/enrichment-of-il-17-producing-cd4-t-cells-in-synovial-fluid-from-patients-with-arthritis-after-anti-ctla-4-and-anti-pd-1-combination-therapy/